| Revenue growth | FY26 revenue up 28% YoY to ₹642.3cr. |
|---|---|
| Margins | EBITDA margin compressed to 34.6% due to high RM costs. |
| Order book | 500 MT purchase order from leading Indian player for battery materials. |
| Demand visibility | Healthy demand across verticals; encouraging traction in advanced materials. |
| Management confidence | High; citing strategic milestones and long-term growth trajectory. |
Growth
FY26 Revenue grew 28% YoY to ₹642.3cr; PAT increased 26% to ₹174.3cr. Q4FY26 revenue rose 16% YoY.
Outlook
Commissioning Dahej battery materials plant early CY2027; Phase 1 capacity 25,000 MT. Targeting 100,000 MT by 2030.
Risks
High raw material costs (phosphoric/sulphuric acid), West Asia conflict supply chain disruptions, and gas supply issues.
Earnings Call filed with NSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,164.90
- Market cap
- ₹13,157 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 72.0×Sector 50.4×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 1.81%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Other Announcement
Sudeep Pharma cancelled its analyst/investor plant visit scheduled for 23–24 September 2026 due to exigencies. No financial or operational impact is indicated.
Sudeep Pharma Investor Presentation: Key Takeaways
Sudeep Pharma reported strong Q1FY27 performance with 27% YoY revenue growth. Strategy focuses on expanding into Specialty Ingredients and high-growth Battery Materials (SAM project).
Sudeep Pharma Q1 FY27 Results: Net Profit ₹40.6 Cr, Up 29.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹158.3 Cr (+26.7% YoY) and net profit of ₹40.6 Cr (+29.7% YoY) for Q1 FY27.
- Key figure
- Net profit ₹40.6 Cr · +29.7% YoY
Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma reported strong H1 FY26 growth, despite Q2 US tariff headwinds causing temporary revenue slippage. The transition towards high-margin specialty ingredients and battery materials via the 'Sam' vertical defines their strategic pivot.
Sudeep Pharma Earnings Call: Key Takeaways
Sudeep Pharma reported 27.9% YoY revenue growth in FY26 to ₹642.3cr, driven by specialty ingredients and international expansion. Management is pivoting towards high-value mineral molecules and a major entry into battery materials.
Sudeep Pharma Q4 FY26 Results: Net Profit ₹48.5 Cr, Up 9.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹182.3 Cr (+15.7% YoY) and net profit of ₹48.5 Cr (+9.7% YoY) for Q4 FY26.
- Key figure
- Net profit ₹48.5 Cr · +9.7% YoY